0000950170-24-073668.txt : 20240614
0000950170-24-073668.hdr.sgml : 20240614
20240614161503
ACCESSION NUMBER: 0000950170-24-073668
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240612
FILED AS OF DATE: 20240614
DATE AS OF CHANGE: 20240614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ashiya Mona
CENTRAL INDEX KEY: 0001794070
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39438
FILM NUMBER: 241044949
MAIL ADDRESS:
STREET 1: C/O SIERRA ONCOLOGY, INC.
STREET 2: 2150 - 885 WEST GEORGIA STREET
CITY: VANCOUVER, BRITISH COLUMBIA
STATE: Z4
ZIP: V6C 3E8
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Disc Medicine, Inc.
CENTRAL INDEX KEY: 0001816736
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 851613057
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 674-9274
MAIL ADDRESS:
STREET 1: 321 ARSENAL STREET, SUITE 101
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: Gemini Therapeutics, Inc. /DE
DATE OF NAME CHANGE: 20210209
FORMER COMPANY:
FORMER CONFORMED NAME: FS Development Corp.
DATE OF NAME CHANGE: 20200702
4
1
ownership.xml
4
X0508
4
2024-06-12
0001816736
Disc Medicine, Inc.
IRON
0001794070
Ashiya Mona
C/O DISC MEDICINE, INC.
321 ARSENAL STREET, SUITE 101
WATERTOWN
MA
02472
true
false
false
false
false
Stock Option (Right to Buy)
38.85
2024-06-12
4
A
false
10000
0.00
A
2034-06-11
Common Stock
10000
10000
D
The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
Pursuant to an agreement with OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC, OrbiMed Capital GP VI LLC, and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP and OrbiMed Private Investments VIII, LP.
By: /s/ Rahul Khara, as Attorney-in-Fact
2024-06-14